Endometriosis affects roughly 1 in 10 women worldwide, and for over a century it was dismissed as “just bad period pain.”
This year, three breakthroughs are starting to change that: a urine test that could cut diagnosis from nine years to days, a blood test overturning a 100-year-old assumption about the disease, and a scan that can spot it without surgery.
None of it happened by accident. It’s the result of a decade of patients refusing to stay quiet, and that noise rewired where research money went. This is the story, told as a timeline.
What is endometriosis?
Endometriosis is a chronic condition where tissue similar to the uterine lining grows outside the uterus, usually on the ovaries, fallopian tubes, or pelvic lining. Sometimes it grows elsewhere in the body, too. That tissue acts like the uterine lining: it thickens and bleeds with the menstrual cycle. As a result, it causes inflammation, scarring, often severe chronic pain, and in some cases infertility.
A century of being disbelieved (1860 – 2013)
Karl von Rokitansky, a pathologist, first described endometriosis in the medical literature in 1860. Sixty-seven years passed before the American gynaecologist John Sampson gave it the name we use today, in a 1927 paper. For most of the twentieth century, diagnosing it required invasive exploratory surgery. Because that bar was so high, doctors chronically under-diagnosed the disease and routinely wrote it off as ordinary period pain. As a result, it attracted almost no research funding, so nobody made progress on faster, non-surgical ways to diagnose it.
The first real cracks came from patients, not clinicians. In 1993, the Endometriosis Association launched the first Endometriosis Awareness Month. Then, in 2009, Padma Lakshmi co-founded the Endometriosis Foundation of America with her surgeon, Dr Tamer Seckin. Lakshmi, a model, cookbook author, and long-term endometriosis patient, gave the disease a public face for the first time. Four years later, in 2013, the Worldwide EndoMarch began. It became one of the first coordinated global advocacy movements built specifically around the disease.
In 2018 patient anger went digital (2018 – 2022)
Social media changed the scale of the pressure. Patients had spent years hearing that their pain was normal, so they turned to Instagram, and later TikTok, to describe what a decade-long diagnostic odyssey actually felt like.
In 2018, the “I am #1in10” campaign went viral. That same year, Australia became the first country in the world to publish a National Action Plan for Endometriosis in a direct response to sustained public pressure.
The political response accelerated from there. The US House Endometriosis Caucus launched in 2020. For the first time, the disease had a standing presence in Congress.
Then, in 2022, the UK published its Women’s Health Strategy for England, naming endometriosis diagnostic delays as a problem to fix.
France launched its own national endometriosis strategy that same year, running to 2025. None of this was a spontaneous act of institutional goodwill. Instead, each step followed years of public campaigning and patient testimony.
Fresh funding for endometriosis research (2017 – 2024)
In the UK, advocacy, funding, and research breakthroughs show a clear pattern.Government health research funding for endometriosis sat at just £494,000 in 2019/20. By 2023/24, it had reached £1.3 million.
Meanwhile, UK Research and Innovation backed a further £8.43 million in endometriosis grants across the same five years This money accounted for three of the described major breakthroughs below.
A similar pattern shows up in the US. National Institutes of Health (NIH) funding for endometriosis research sat at just $6 million in 2017. By 2024, it had reached $28 million. That increase coincided almost exactly with the period of loudest public pressure. This year two NIH grants backed Yale’s January 2026 blood test for early-stage endometriosis.
Still, it’s worth being honest about what these numbers mean in context. NIHR spent £1.3 billion on research in total in 2023/24. So endometriosis’s £1.3 million funding works out to roughly 0.1% of that whole budget for a disease affecting one in ten women. This figure sits inside a much wider gender health gap in how medical research gets funded.
Endometriosis breakthroughs (April – July 2026)
Researchers published three big results this year. Together, they show what that funding is starting to buy.
A urine test that could replace years of waiting. Dr Barbara Guinn and her team at the University of Hull developed EndoTect, a non-invasive urine test. It can distinguish deep endometriosis from superficial endometriosis. The test aims to cut a diagnostic process that currently takes seven to nine years, on average. It could bring that down to just days, without a hospital visit.
A scan that finds what once needed surgery. Oxford researchers published the DETECT study in The Lancet in April 2026. The scan could highlight endometriosis lesions, including hard-to-find superficial ones, across a small group of 19 patients. It’s still an early-stage, Phase 2 result on a small sample, but the results are promising.
A blood test that challenges a 100-year-old assumption. University of Edinburgh researchers reported a striking discovery in July 2026. People with endometriosis have a distinct hormonal “fingerprint” that pushes back on a long-standing assumption that endometriosis is purely an oestrogen-driven disease. It also opens the door to new categories of targeted drug treatment.
A case study in advocacy, with an honest caveat (2017 – 2026)
Research pipelines move slowly. In fact, grants and academic groundwork from years earlier seeded the studies breaking through in 2026. Several of them predate the viral peak of the advocacy movement. However, sustained, specific, and well-organised pressure can change institutional priorities and funding. Endometriosis shows that where research money goes is a policy choice, not a fixed law of scientific progress.
Public pressure and increased visibility has influenced what research got funded, but it has yet to influence some other problems. The average UK diagnostic has since risen to nine years and four months in the most recent report, but hopefully the recent breakthroughs will cut that number down.
Across women’s health, listening to lived experience, not just lab data, has repeatedly moved the needle. That lesson now needs to travel further, to cover facets of women’s health that have been historically under-researched, such as pain management and menopause.
Where this leaves patients now
None of the three 2026 breakthroughs are available in a GP’s office yet. EndoTect and the Edinburgh hormone panel are still moving through validation.
The DETECT scan, too, is only an early-phase result. Now, the real work is keeping the pressure on, rather than assuming the job is done. That’s what turns this year’s pilot studies into next decade’s standard of care.
Sources referenced: Yale School of Medicine (microRNA biomarker study, January 2026); University of Hull (EndoTect, May 2026); The Lancet / Oxford NIHR Biomedical Research Centre (DETECT study, April 2026); University of Edinburgh (11-oxygenated androgen study, July 2026); UK Parliament and UK Research and Innovation (UK funding data); National Health Executive (NIHR total budget); Statista and Endometriosis Foundation of America (NIH funding data); RCOG and Endometriosis UK (UK diagnostic delay reporting); Endometriosis Australia, GOV.UK, and Endometriosis.org (national action plans); Iowa State University archive and The 19th News (House Endometriosis Caucus).
The Timeline of Endometriosis
The timeline below traces this whole history, decade by decade. It also names two campaigners who didn’t live to see this progress: Aubrion Rogers and Jahmby Koikai spent their lives pushing for exactly the kind of change this piece describes, and both died from complications of the disease itself.
